The Pro Medicus Ltd (ASX: PME) share price has pulled back sharply in recent weeks.
Shares in the medical imaging software leader are down 13%, despite no change in the company's underlying fundamentals.
At Friday's close, Pro Medicus shares finished the session at $217.37.
For a stock that has delivered consistently over the long run, the recent weakness raises the question of whether the market has become too cautious.
Image source: Getty Images
A rare pullback in a premium business
Pro Medicus has built a reputation as one of the highest-quality software companies on the ASX. Its Visage Imaging platform is deeply embedded in large hospital networks, particularly across the US, where long contract durations and high switching costs create a powerful moat.
The recent share price weakness appears more about valuation concerns and broader market volatility than company-specific issues. There have been no profit warnings, no loss of major customers, and no slowdown in contract momentum.
Contract wins continue to stack up
Just weeks ago, Pro Medicus announced another significant long-term contract with a large US healthcare group. The agreement covers a multi-year rollout across the customer's network, with room to expand over time.
That lines up with what management outlined at the latest AGM. Demand from US hospital systems remains strong, sales pipelines are deep, and existing customers continue to expand the platform's footprint.
Brokers remain firmly bullish
Despite the recent pullback, broker views on Pro Medicus haven't really changed.
Most major brokers continue to rate the stock as a buy, pointing to its long-term growth profile and ability to scale earnings as contracts roll through. Price targets remain comfortably above current levels, with many sitting in the $250 to $280 range.
Bell Potter has again highlighted Pro Medicus as a preferred healthcare name heading into 2026, citing its strong competitive position and clear revenue visibility. Similar themes are coming through across other broker updates, with analysts still seeing upside as new contracts ramp up and margins continue to expand.
Foolish takeaway
Rather than focusing on whether Pro Medicus is cheap, the real question is whether anything has changed. Right now, it's business as usual.
Contract momentum remains solid, broker confidence hasn't wavered, and management continues to point to a deep pipeline of US opportunities. In that context, the recent pullback looks more like a shift in sentiment than any change in the underlying story.
For investors watching the stock, this phase may be less about picking the exact bottom and more about gradually building exposure to a high-quality ASX 200 company.
